U.S. Markets closed
  • S&P Futures

    3,450.25
    +18.00 (+0.52%)
     
  • Dow Futures

    28,316.00
    +134.00 (+0.48%)
     
  • Nasdaq Futures

    11,722.75
    +62.00 (+0.53%)
     
  • Russell 2000 Futures

    1,625.40
    +10.60 (+0.66%)
     
  • Crude Oil

    41.51
    +0.05 (+0.12%)
     
  • Gold

    1,922.50
    +7.10 (+0.37%)
     
  • Silver

    25.16
    +0.18 (+0.72%)
     
  • EUR/USD

    1.1848
    +0.0020 (+0.1659%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2971
    +0.0024 (+0.1868%)
     
  • USD/JPY

    105.3700
    -0.1000 (-0.0948%)
     
  • BTC-USD

    12,171.19
    +1,114.18 (+10.08%)
     
  • CMC Crypto 200

    244.10
    +5.19 (+2.17%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,676.90
    +109.86 (+0.47%)
     

LEGEND BIOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Legend Biotech Corporation on Behalf of Legend Biotech Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire
·2 mins read

NEW YORK, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Legend Biotech Corporation (NASDAQ: LEGN) on behalf of Legend Biotech stockholders. Our investigation concerns whether Legend Biotech has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On September 21, 2020, Legend issued a press release announcing that its Chief Executive Officer, Dr. Fangliang Zhang, has been placed under residential surveillance by Chinese law enforcement authorities. In addition, Legend announced that the Chinese Customs Anti-Smuggling Department has inspected certain business facilities of GenScript Biotech Corporation, Legend’s parent and majority shareholder, in connection with suspected violations of import and export regulations under Chinese law.

On this news, Legend’s stock price fell sharply on September 21, 2020, to close at $27.50 per share.

If you purchased or otherwise acquired Legend Biotech shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com